MCM
CRSP icon

MV Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

MV Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.46K Buy
45
+36
+400% +$1.9K ﹤0.01% 753
2026
Q1 		$429 Sell
9
-28
-76% -$1.48K ﹤0.01% 998
2025
Q4 		$1.94K Hold
37
– – ﹤0.01% 727
2025
Q3 		$2.4K Hold
37
– – ﹤0.01% 689
2025
Q2 		$1.8K Sell
37
-8
-18% -$310 ﹤0.01% 713
2025
Q1 		$1.53K Buy
45
+43
+2,150% +$1.82K ﹤0.01% 718
2024
Q4 		$79 Buy
+2
New +$94 ﹤0.01% 979
2024
Q3 		– Sell
-3
Closed -$163 – 1063
2024
Q2 		$163 Buy
+3
New +$174 ﹤0.01% 823

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MV Capital Management's CRSP Position: Q2 2026 in Review

MV Capital Management increased its CRISPR Therapeutics (CRSP) stake by 400% in Q2 2026, buying an estimated $1.9K and bringing the position to 45 shares worth $2.46K. The position accounts for ﹤0.01% of the portfolio, ranked #753.

MV Capital Management first reported a position in CRSP in Q2 2024 and has held it in 8 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • MV Capital Management held 45 shares of CRISPR Therapeutics worth $2.46K as of Q2 2026.
  • MV Capital Management bought 36 CRISPR Therapeutics shares in Q2 2026, an estimated $1.9K.
  • CRISPR Therapeutics made up ﹤0.01% of MV Capital Management's portfolio in Q2 2026, its #753 holding.
  • MV Capital Management first reported a position in CRISPR Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on MV Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.